GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sichuan Kelun-Biotech Biopharmaceutical Co Ltd (HKSE:06990) » Definitions » Cash Flow from Financing

Sichuan Kelun-Biotech Biopharmaceutical Co (HKSE:06990) Cash Flow from Financing : HK$-20.6 Mil (TTM As of Dec. 2023)


View and export this data going back to 2023. Start your Free Trial

What is Sichuan Kelun-Biotech Biopharmaceutical Co Cash Flow from Financing?

Cash from financing is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders.

For the three months ended in Dec. 2023, Sichuan Kelun-Biotech Biopharmaceutical Co paid HK$0.0 Mil more to buy back shares than it received from issuing new shares. It received HK$0.0 Mil from issuing more debt. It paid HK$0.0 Mil more to buy back preferred shares than it received from issuing preferred shares. It received HK$0.0 Mil from paying cash dividends to shareholders. It received HK$0.0 Mil on other financial activities. In all, Sichuan Kelun-Biotech Biopharmaceutical Co spent HK$0.0 Mil on financial activities for the three months ended in Dec. 2023.


Sichuan Kelun-Biotech Biopharmaceutical Co Cash Flow from Financing Historical Data

The historical data trend for Sichuan Kelun-Biotech Biopharmaceutical Co's Cash Flow from Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sichuan Kelun-Biotech Biopharmaceutical Co Cash Flow from Financing Chart

Sichuan Kelun-Biotech Biopharmaceutical Co Annual Data
Trend Dec21 Dec22 Dec23
Cash Flow from Financing
792.62 350.04 2,605.69

Sichuan Kelun-Biotech Biopharmaceutical Co Quarterly Data
Sep21 Dec21 Jun22 Sep22 Dec22 Jun23 Dec23
Cash Flow from Financing Get a 7-Day Free Trial - -2.49 -18.09 - -

Sichuan Kelun-Biotech Biopharmaceutical Co Cash Flow from Financing Calculation

This is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders. In the calculation of free cash flow, cash from financing is not calculated because it is not related to operating activities.

Sichuan Kelun-Biotech Biopharmaceutical Co's Cash from Financing for the fiscal year that ended in Dec. 2023 is calculated as:

Sichuan Kelun-Biotech Biopharmaceutical Co's Cash from Financing for the quarter that ended in Dec. 2023 is:


Cash Flow from Financing for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was HK$-20.6 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Sichuan Kelun-Biotech Biopharmaceutical Co  (HKSE:06990) Cash Flow from Financing Explanation

Cash from financing contains six items:

1. Issuance of Stock:
A company may raise cash from issuing new shares. Issuance of stock represents the cash inflow from offering common stock, which is the additional capital contribution to the entity during the period.

Sichuan Kelun-Biotech Biopharmaceutical Co's issuance of stock for the three months ended in Dec. 2023 was HK$0.0 Mil.

2. Repurchase of Stock:
A company may raise cash from issuing new shares. It can also use cash to buy back shares. Repurchase of stock represents the cash outflow to reacquire common stock during the period.

Sichuan Kelun-Biotech Biopharmaceutical Co's repurchase of stock for the three months ended in Dec. 2023 was HK$0.0 Mil.

3. Net Issuance of Debt:
Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.

Sichuan Kelun-Biotech Biopharmaceutical Co's net issuance of debt for the three months ended in Dec. 2023 was HK$0.0 Mil. Sichuan Kelun-Biotech Biopharmaceutical Co received HK$0.0 Mil from issuing more debt.

4. Net Issuance of Preferred Stock:
A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.

Sichuan Kelun-Biotech Biopharmaceutical Co's net issuance of preferred for the three months ended in Dec. 2023 was HK$0.0 Mil. Sichuan Kelun-Biotech Biopharmaceutical Co paid HK$0.0 Mil more to buy back preferred shares than it received from issuing preferred shares.

5. Cash Flow for Dividends:
Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.

Sichuan Kelun-Biotech Biopharmaceutical Co's cash flow for dividends for the three months ended in Dec. 2023 was HK$0.0 Mil. Sichuan Kelun-Biotech Biopharmaceutical Co received HK$0.0 Mil from paying cash dividends to shareholders.

6. Other Financing:
Money spent or earned by company from other financial activities.

Sichuan Kelun-Biotech Biopharmaceutical Co's other financing for the three months ended in Dec. 2023 was HK$0.0 Mil. Sichuan Kelun-Biotech Biopharmaceutical Co received HK$0.0 Mil on other financial activities.


Sichuan Kelun-Biotech Biopharmaceutical Co Cash Flow from Financing Related Terms

Thank you for viewing the detailed overview of Sichuan Kelun-Biotech Biopharmaceutical Co's Cash Flow from Financing provided by GuruFocus.com. Please click on the following links to see related term pages.


Sichuan Kelun-Biotech Biopharmaceutical Co (HKSE:06990) Business Description

Traded in Other Exchanges
N/A
Address
No. 666 Xinhua Avenue, Chengdu Cross-Strait Science and Technology Industry Development Park, Wenjiang, Sichuan, Chengdu, CHN
Sichuan Kelun-Biotech Biopharmaceutical Co Ltd is an innovative biopharmaceutical company committed to the R&D, manufacturing and commercialization of novel drugs to address medical needs in China and globally. It is one of the first movers in the development of antibody-drug conjugates (ADCs), with over a decade of accumulated experience in ADC development. The company takes a systematic, indication-oriented approach to target the world's prevalent or hard-to-treat cancers, and other diseases and conditions affecting a large and underserved population.
Executives
Liu Gexin 2201 Interest of corporation controlled by you
Si Chuan Ke Lun Yao Ye Gu Fen You Xian Gong Si 2201 Interest of corporation controlled by you
Cheng Du Ke Lun Jing Chuan Ke Ji You Xian Gong Si 2201 Interest of corporation controlled by you
Wellington Management Group Llp 2102 Investment manager
Merck & Co., Inc. 2201 Interest of corporation controlled by you
Merck Sharp & Dohme Llc 2101 Beneficial owner
Ke Lun Guo Ji Fa Zhan You Xian Gong Si 2101 Beneficial owner
Li Jun 2201 Interest of corporation controlled by you
Zhou Quan 2201 Interest of corporation controlled by you
Idg Breyer Capital Fund Gp Associates L.p. 2201 Interest of corporation controlled by you
Idg Breyer Capital Fund Gp Associates Ltd. 2201 Interest of corporation controlled by you
Idg Breyer Capital Fund L.p. 2201 Interest of corporation controlled by you
Victory Rhythm Limited 2201 Interest of corporation controlled by you
Wealthy Linkage Limited 2101 Beneficial owner
Ho Chi Sing 2201 Interest of corporation controlled by you

Sichuan Kelun-Biotech Biopharmaceutical Co (HKSE:06990) Headlines

No Headlines